Prognostic significance of proteolytic enzymes in human brain tumors.
Proteases and their inhibitors have been shown to play roles in tumor invasion and metastasis in a number of experimental models. Recently, relative increases in the amounts of urokinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in tumor samples have been correlated with poorer, pathological grade, shorter disease-free interval, and shorter survival. To date, all studies investigating the prognostic significance of proteases and their inhibitors have been limited to extracranial cancer. In this article, we review the literature and present our data on the prognostic significance of proteases in human brain tumors. High levels of uPA were seen in malignant glioma and metastatic tumors (n = 82), whereas normal levels of uPA were found in low-grade gliomas. Analysis with magnetic resonance imaging (MRI) demonstrated a significant correlation between high levels of uPA and necrosis and edema (n = 50; P < 0.05). Similarly, patients with high levels of uPA had shorter survival than did patients with low levels of uPA. Tissue-type plasminogen activator (tPA), which was virtually absent in glioblastoma multiforme (GBM), colon lung, and breast metastasis, was found in normal quantities in anaplastic astrocytoma (AA), low-grade glioma (LGG), and meningioma. Melanoma had significantly more tPA activity than normal brain did. A reverse correlation was found between tPA and MRI findings of necrosis, enhancement, and edema. Similarly, patients with no detectable tPA activity had shorter survival than did patients with detectable tPA activity. We conclude that high levels of uPA and absent tPA activity correlate with histologically malignant brain tumors, aggressive characteristics, and shorter survival.
Bindal
A K
AK
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Hammoud
M
M
Shi
W M
WM
Wu
S Z
SZ
Sawaya
R
R
Rao
J S
JS
D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000150:complications / Q000175:diagnosis / Q000201:enzymology*; D010450:Endopeptidases / Q000378:metabolism; D006801:Humans; D008279:Magnetic Resonance Imaging; D009369:Neoplasms / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000150:complications; D010447:Peptide Hydrolases / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism; D011379:Prognosis; D016019:Survival Analysis
D010450:Endopeptidases; D010447:Peptide Hydrolases; D010960:Plasminogen Activators